Synergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells.

about

Vitamin K and hepatocellular carcinoma: The basic and clinic Vitamin K and its analogs: Potential avenues for prostate cancer management.Research progress on the anticancer effects of vitamin K2.

P2860

Q26783713-7869A9D0-A4DB-472F-B926-DB75B2DBCBB3 Q41339709-A70986E8-66D7-4324-8DF1-FF5CE3C0424F Q55261096-E07E8228-7D3E-4A7C-8262-9401B05C8F7F

P2860

Synergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells.

Item

http://www.wikidata.org/entity/Q36223025

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Synergistic growth inhibition ...... epatocellular carcinoma cells.

@ast

Synergistic growth inhibition ...... epatocellular carcinoma cells.

@en

type

Item

label

Synergistic growth inhibition ...... epatocellular carcinoma cells.

@ast

Synergistic growth inhibition ...... epatocellular carcinoma cells.

@en

prefLabel

Synergistic growth inhibition ...... epatocellular carcinoma cells.

@ast

Synergistic growth inhibition ...... epatocellular carcinoma cells.

@en

P1476

Synergistic growth inhibition ...... epatocellular carcinoma cells.

@en

P2093

Anran Zhang

http://www.w3.org/2001/XMLSchema#string

Bicheng Zhang

http://www.w3.org/2001/XMLSchema#string

Dianchun Fang

http://www.w3.org/2001/XMLSchema#string

Jian Liu

http://www.w3.org/2001/XMLSchema#string

Jianfei Gao

http://www.w3.org/2001/XMLSchema#string

Jie Zhao

http://www.w3.org/2001/XMLSchema#string

Yafei Zhang

http://www.w3.org/2001/XMLSchema#string

Yong Zhao

http://www.w3.org/2001/XMLSchema#string

Zhiguo Rao

http://www.w3.org/2001/XMLSchema#string

P2860

Hepatocellular carcinoma: agents and concepts for preventing recurrence after curative treatment

Cyclin D as a therapeutic target in cancer

p21 is a universal inhibitor of cyclin kinases

Hepatocellular carcinoma

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

Primary liver cancer: worldwide incidence and trends

Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors.

Clinical and epidemiological aspects of hepatocellular carcinoma in Brazil.

Curcumin, but not Prima-1, decreased tumor cell proliferation in the syngeneic murine orthotopic bladder tumor model.

p21 stability: linking chaperones to a cell cycle checkpoint.

P304

1093-1099

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.6061/CLINICS/2012(09)18

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

231224574

http://www.w3.org/2001/XMLSchema#string

P698

23018309

http://www.w3.org/2001/XMLSchema#string

P921

vitamin K

P932

3438252

http://www.w3.org/2001/XMLSchema#string

Synergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells.

about

P2860

P2860

Synergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P932